Real-world evidence comes of age: how routine data strengthens medicine
Clinical trials tell us what a medicine can do; real-world evidence tells us what it does in everyday care. Modern medicine needs both.
Every day of routine care generates evidence. Electronic health records, insurance claims and disease registries capture how treatments perform in the patients trials rarely fully represent — older, multimorbid, taking many medicines, living ordinary lives. Real-world evidence (RWE) turns this information into knowledge, and its standing has matured decisively: in 2024 the US Food and Drug Administration finalised guidance on assessing electronic health records and claims data to support regulatory decision-making.[1]
Why rigour makes or breaks RWE
Routine data was never designed for research, which is precisely why RWE is a discipline rather than a shortcut:
- Design before data. Trustworthy studies specify questions, comparators and analyses up front — observational does not mean improvised.
- Know the data’s biography. Coding practices, care pathways and record habits shape every dataset; interpreting results means understanding how the data came to be.
- Confounding honesty. Real-world comparisons demand careful methods and transparent limitations — credibility is the product.
- Fitness for purpose. The same dataset may be excellent for one question and unsuitable for another; judging that fit is core professional skill.
The way forward
RWE now complements trials across the medicine lifecycle — informing safety monitoring, effectiveness questions, and health-system decisions. As data infrastructure grows across Europe and beyond, the limiting factor is not data but people: professionals who can design credible studies and communicate them honestly.
Observational science grows up
Learning from routinely observed health data is not new — it is one of medicine’s oldest instincts. The Framingham Heart Study, following a Massachusetts community since 1948, showed how observation of ordinary lives could define the very concept of a risk factor; decades of registry science in Scandinavia and beyond demonstrated that well-kept routine records could answer questions trials never could. What the last decade added was formal recognition: legislation such as the US 21st Century Cures Act of 2016 directed regulators to evaluate the use of real-world evidence for regulatory decisions, and agencies on both sides of the Atlantic built frameworks, guidance and infrastructure to use routine data deliberately rather than opportunistically.
The intellectual shift matters as much as the legal one. The old dichotomy — randomised trials as truth, observational data as anecdote — has given way to a more mature question: which design, applied to which data, answers which question credibly? Trials remain the gold standard for demonstrating efficacy; real-world studies excel at long-term safety, effectiveness in populations trials exclude, patterns of actual use, and the performance of medicines under the friction of ordinary care.
The craft of credible real-world studies
- Fitness-for-purpose data. Understanding how the data was generated — and therefore what it systematically misses — before trusting what it shows.
- Design before analysis. Pre-registered protocols, explicit target trials to emulate, and analysis plans fixed before results are seen — the disciplines that separate evidence from exploration.
- Bias confronted, not assumed away. Confounding, immortal time, selection effects — named, quantified where possible, and honestly bounded where not.
- Transparency end to end. Code, definitions and provenance documented so a sceptical reviewer can retrace every step.
Looking ahead
Infrastructure is compounding: common data models spanning hundreds of millions of patients, federated networks that analyse data where it lives, and Europe’s health data space promising harmonised access. As the pipes improve, the scarce resource becomes people — professionals who combine epidemiological rigour with data fluency and regulatory awareness. Real-world evidence has come of age; the careers built on it are just getting started.
The career signal: RWE roles span pharma, regulators, HTA bodies and hospitals — one of the most portable evidence careers in modern healthcare.
Where EUSTM fits
The EUSTM Academy’s Professional Certification in Real-World Evidence (PCRWE) recognises this competence directly, and pairs naturally with the Professional Certification in Health Economics & Outcomes Research (PCHEOR) where evidence meets value assessment.
References
- Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products — final guidance. US Food and Drug Administration (2024). www.fda.gov
Disclaimer. This Expert Insight is provided by EUSTM for general informational and educational purposes only. It does not constitute medical, clinical, legal, regulatory or other professional advice, and it should not be relied upon as the basis for clinical, regulatory or business decisions. While care is taken in preparing this content, EUSTM makes no representation or warranty as to the accuracy, completeness or currency of any scientific, medical or other statements, and accepts no liability arising from the use of this content. Readers should consult the cited sources, the current official guidance of the relevant authorities and frameworks, and appropriately qualified professionals in their own jurisdiction. References to third-party organisations, publications or frameworks are for information only and do not imply affiliation or endorsement.
← All Expert Insights